EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The EMA authorised Skyrizi (risankizumab) for multiple indications. This expands its approved uses to psoriasis, psoriatic arthritis, ulcerative colitis, and Cr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis
• Ulcerative Colitis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Status: Authorised. Therapeutic area: Psoriasis;Arthritis, Psoriatic;Colitis, Ulcerative;Crohn Disease. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 14/10/2025